Achieving a flexible, integrated, and sustainable cryogenic cold chain ecosystem Critical first and final steps in a cell therapy’s journey to clinic

The agenda for this event has been developed in collaboration with Cytiva and the Cell and Gene Therapy Catapult.

11:00 am Welcome and introductory remarks

Panel Discussion

11:15 am Panel Discussion Overview:

  • Beth Webb Commercial GM, Cell & Gene Therapy, Cytiva
  • Dr Stephen Ward Chief Manufacturing Officer, Cell and Gene Therapy Catapult
  • David Brochu Chief Technical Officer, Autolus Therapeutics
  • Alex Guite, Ph.D Vice President, Services and Alliances, AmerisourceBergen
    World Courier & ICS


During this discussion, our panel will examine the cell and gene therapy solutions that have been designed to overcome challenges in the cryogenic cold chain ecosystem. Looking ahead, we will consider what continued developments are needed to ensure end-to-end sustainability of this ecosystem.

By highlighting lessons learned from the COVID-19 pandemic, panelists will also emphasize the importance of both sustainable and automated cell and gene therapy processing to maintain a continuous supply chain and deliver critical treatments to clinic.

Case studies

12:00 pm Session Introduction

12:15 pm Case Studies

  • Amittha Wickrema, Ph.D. Professor of Medicine, Director, Advanced Cellular Therapeutics Facility, Faculty Director, Cellular & Tissue based Processing cGMP Facility Hematology/Oncology Section, Dept. of Medicine, University of Chicago
  • Christopher Herbert Director of Operations, Research and Innovation, Leeds Teaching Hospitals NHS Trust


Invited speakers will share their experiences with case study examples of how implementation of flexible, automated, and integrated solutions is leading the way to a sustainable cryogenic cold chain ecosystem.

Technology spotlight

1:15 pm Session introduction

1:30 pm Technology Spotlight


Learn how Cytiva has worked with other key industry players to close the gap in the cryogenic cold chain ecosystem through the development of solutions that:

  • Reduce complexity and variation of initial patient sample.
  • Enable a reliable, efficient, and safe supply chain for ATMP starting material.
  • Ensure robust processes are in place for delivery into the clinical setting.